Two-Arm, Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects With Relapsed/Refractory CLL, SLL, or FL and an Open-Label Study of ME-401 With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL
Phase of Trial: Phase I
Latest Information Update: 09 May 2018
At a glance
- Drugs ME 401 (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Proof of concept
- Sponsors MEI Pharma
- 09 May 2018 According to a MEI Pharma media release, data from this trial will be presented at the 2018 American Society of Clinical Oncology Annual Meeting.
- 06 Feb 2018 Planned number of patients changed from 156 to 126.
- 18 Dec 2017 Planned number of patients changed from 84 to 156.